SK Chemicals’ hemophilia treatment, a biopharmaceutical new drug, is about to be approved in the U.S.
The U.S. approval procedure of the hemophilia treatment developed by a domestic pharmaceutical company has been accelerated.
SK Chemicals(President Man-hoon Park) announced on the 29th that it has completed application for the FDA’s marketing approval of its self-developed hemophilia treating bi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
